Home ›
Endometrial Cancer Uterine Cancer Trials ›
NCT07209449
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
The researchers are doing this study to find out whether elacestrant is an effective and safe treatment alone or in combination with abemaciclib for people with advanced or recurrent ER+ endometrial cancer.
Trial Details
NCT ID NCT07209449
Phase PHASE2
Sponsor Memorial Sloan Kettering Cancer Center
Status RECRUITING
Cancer Type Endometrial Cancer Uterine Cancer
Interventions
Locations (sample) Basking Ridge, New Jersey, United States|40.70621,-74.54932 Middletown, New Jersey, United States|40.39428,-74.11709 Montvale, New Jersey, United States|41.04676,-74.02292 Commack, New York, United States|40.84288,-73.29289 Harrison, New York, United States|40.96899,-73.71263
Key Eligibility Criteria
Age ≥18 years at the time of informed consent. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Patients must have received previous platinum-based chemotherapy Patients may have received no more than 2 prior lines of therapy for management of endometrial carcinoma. This includes platinum-based chemotherapy…
For full eligibility, visit ClinicalTrials.gov .